EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news
Issue link: https://daily.eyeworld.org/i/124062
ASCRS News Today Business meeting highlights ASCRS achievements www.AcrySofReSTOR.com by Erin L. Boyle EyeWorld Senior Staff Writer CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician. INDICATIONS: The AcrySof® IQ ReSTOR® Posterior Chamber Intraocular Lens (IOL) is intended for primary implantation for the visual correction of aphakia secondary to removal of a cataractous lens in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. The lens is intended to be placed in the capsular bag. WARNING/PRECAUTION: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/ benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia, and ensure that IOL centration is achieved. Care should be taken to remove viscoelastic from the eye at the close of surgery. Some patients may experience visual disturbances and/or discomfort due to multifocality, especially under dim light conditions. Clinical studies with the AcrySof® ReSTOR® lens indicated that posterior capsule opacification (PCO), when present, developed earlier into clinically significant PCO. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product informing them of possible risks and benefits associated with the AcrySof® IQ ReSTOR® IOLs. Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof® Natural IOL and normal color vision. The effect on vision of the AcrySof® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS® or BSS PLUS® Sterile Intraocular Irrigating Solutions. ATTENTION: Reference the Directions for Use labeling for a complete listing of indications, warnings and precautions. M embership is up for ASCRS, said incoming president Eric D. Donnenfeld, MD, East Meadow, N.Y., at the business meeting following the ASCRS Opening General Session. "Membership is at an all-time high, that's the most important thing that I can tell you," Dr. Donnenfeld said. The ASCRS membership is comprised of about 50% U.S. physicians and 40% international physicians, with the remaining 10% comprised of different groups such as young physicians, residents, military, emerging nations, and retired physicians, he said. The membership currently totals 9,142 members. In addition, ASCRS generated a profit last year, he said, with the 2013 ASCRS budget expenses at more than $19 million. He said that advocacy is a large part of ASCRS, with a focus on various issues including Medicare physician payment reform and alternative payment systems. Dr. Donnenfeld said that ASCRS initiatives were discussed in more depth at the ASCRS Opening General Session, so he presented only a brief overview in the business update. "[They] include CME education, the 2013 Annual Clinical Trends Survey, ASCRS Advisory Panel, IOMED, and restructuring marketing and communications, focusing on valueadded content for members," Dr. Donnenfeld said. EW In tune Mixed Company, Stanford's oldest co-ed a cappella group, performs at the ASCRS Opening General Session. The group performs pop, rock, and everything in between and has been featured on several college a cappella compilation albums, including "Best of College A Cappella" and, most recently, "Voices Only 2012." Mixed Company also recently completed their 12th studio album, "The Rush," and is currently working on their 13th album. © 2013 Novartis 1/13 RES12192JAD